Adverse drug reactions to antiretroviral medication

Frontiers in Bioscience

Volumn 14, Issue 5, 2009, Pages 1785-1792

  Roca, Bernardino ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Adverse drug reactions; Antiretroviral treatment; HIV infection; Hypersensitivity reactions; Review

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LACTIC ACID;

BLOOD; BONE MARROW; BONE NECROSIS; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LIPODYSTROPHY; LIVER; METABOLIC BONE DISEASE; NERVOUS SYSTEM; PANCREATITIS; REVIEW; URINARY TRACT;

ANTI-HIV AGENTS; BONE DISEASES, METABOLIC; BONE MARROW; CARDIOVASCULAR SYSTEM; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TRACT; HIV INFECTIONS; HUMANS; LACTIC ACID; LIPODYSTROPHY; LIVER; NERVOUS SYSTEM; OSTEONECROSIS; PANCREATITIS; URINARY TRACT;

EID: 63849311620     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3340     Document Type: Article

References (26)

1. L. Siegel, R. M. Gulick: New antiretroviral agents. Curr Infect Dis Rep 9, 243-251 (2007). (Pubitemid 46736262)
2. S. M. Hammer, M. S. Saag, M. Schechter, J. S. Montaner, R. T. Schooley, D. M. Jacobsen et al: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843 (2006). (Pubitemid 44223106)
3. Panel on Antiretroviral Guidelines for Adult and Adolescents: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. 1-113. (2006).
4. A. Calmy, B. Hirschel, D. A. Cooper, A. Carr: Clinical update: adverse effects of antiretroviral therapy. Lancet 370, 12-14 (2007). (Pubitemid 47017451)
5. E. Phillips, S. Mallal: Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 7, 324-330 (2007). (Pubitemid 47052020)
6. L. Waters, L. John, M. Nelson: Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 61, 105-118 (2007).
7. A. Lucas, D. Nolan, S. Mallal: HLA-B15701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 59, 591-593 (2007). (Pubitemid 47073389)
8. N. A. Meanwell, J. F. Kadow: Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 8, 669-681 (2007). (Pubitemid 47205251)
9. M. A. Riedl, A. M. Casillas: Adverse drug reactions: types and treatment options. Am Fam Physician 68, 1781-1790 (2003). (Pubitemid 37385772)
10. P. M. Songa, B. Castelnuovo, E. B. Mugasha, P. Ocama, A. Kambugu: Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda) Clin Infect Dis 45, 514-751 (2007).
11. M. K. Jain: Drug-Induced Liver Injury Associated with HIV Medications. Clin Liver Dis 11, 615-639 (2007). (Pubitemid 47302347)
12. M. Sekimoto, T. Takada, Y. Kawarada, K. Hirata, T. Mayumi, M. Yoshida et al: JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 13, 10-24 (2006). (Pubitemid 43193670)
13. S. Esser, D. Helbig, U. Hillen, J. Dissemond, S. Grabbe: Side effects of HIV therapy. J Dtsch Dermatol Ges 5, 745-754 (2007). (Pubitemid 47382949)
14. L. Waters, L. John, M. Nelson: Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 61, 105-118 (2007).
15. HIV Neuromuscular Syndrome Study Group: HIV-associated neuromuscular weakness syndrome. AIDS 18, 1403-1412 (2004).
16. A. Gonzalez-Duarte, K. Cikurel, D. M. Simpson: Managing HIV Peripheral Neuropathy. Curr HIV/AIDS Rep 4, 114-118 (2007). (Pubitemid 47493051)
17. D. Mildvan, T. Creagh, G. Leitz; The Anemia Prevalence Study Group: Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunod-eficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 23, 343-355 (2007). (Pubitemid 46333383)
18. Z. Temesgen, J. Feinberg: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 45, 761-769 (2007). (Pubitemid 47381280)
19. R. F. Gagnon, A. I. Alli, A. K. Watters, C. M. Tsoukas: Indinavir crystalluria. Kidney Int 70, 2047 (2006). (Pubitemid 44871362)
20. A. Winston, J. Amin, P. Mallon, D. Marriott, A. Carr, D. A. Cooper, S. Emery: Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7, 105-111 (2006).
21. DAD Study Group: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356, 1723-1735 (2007).
22. P. Engelhard: Correction options for lipoatrophy in HIVinfected patients. AIDS Patient Care STDS 20, 151-160 (2006).
23. D. C. Chow, L. J. Day, S. A. Souza, C. M. Shikuma: Metabolic complications of HIV therapy. IAPAC Mon 12, 302-317 (2006).
24. A. L. Lima, A. V. Zumiotti, G. L. Camanho, E. Benegas, A. L. Santos, C. O. D'Elia, P. R. Oliveira: Osteoarticular complications related to HIV infection and highly active antiretroviral therapy. Braz J Infect Dis 11, 426-429 (2007). (Pubitemid 47516800)
25. A. Soria, A. Lazzarin: Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr 46 Suppl 1, S19-30 (2007). (Pubitemid 47315643)
26. J. Reynes, K. Arasteh, B. Clotet, C. Cohen, D. A. Cooper, J. F. Delfraissy et al: TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21, 533-543 (2007). (Pubitemid 350194955)